Rodney
Rodney, 68, with relapsed high-risk DLBCL, accessed dual CD19/CD20 CAR-T therapy in China. Early Day 10 monitoring showed strong CAR-T expansion with no severe toxicity.
Why the Family Contacted CancerFax
Facing a refractory, high-risk lymphoma is overwhelming enough without also having to work out, from another country, which centres offer a specific cell therapy, whether a patient qualifies, and how to physically get there. These were the questions Rodney's family could not easily answer on their own.
Dual-target CAR-T is not widely available. Identifying a centre with genuine experience in it required specialist knowledge.
Eligibility for CAR-T is strict, and questions of age and aggressive biology needed proper medical evaluation.
Records review, translation, hospital communication, and travel logistics all needed coordinating across borders.
"We wanted to know if there was still a real option for him, and we needed someone who could help us find it and reach it."β Rodney's family
How CancerFax Helped
CancerFax facilitated access to treatment for Rodney. That meant organising his case for specialist review, helping identify and coordinate with the treating centre, managing communication across the language barrier, and supporting the practical side of travelling for care.
Medical records, the lymph node biopsy, immunohistochemistry, and prior treatment history were compiled into a structured case file for specialist review.
CancerFax helped identify and coordinate with Lu Daopei Hospital in China as a centre with experience relevant to relapsed, refractory DLBCL.
Communication between Rodney's family and the treating team was managed and translated throughout evaluation and treatment.
Visa documentation, travel planning, and on-the-ground coordination were arranged for Rodney and his accompanying family.
Rodney's Treatment Journey
Key steps from diagnosis through early post-infusion monitoring.
Rodney had been living with DLBCL for around three years. In August 2025 a cervical lymph node biopsy confirmed invasive B-cell lymphoma of germinal-centre origin, with a high-risk profile including a double-expressor pattern (c-MYC and Bcl-2), a BCL2 rearrangement by FISH, and several gene mutations.
He received polatuzumab with a BTK inhibitor and lenalidomide, followed by FC lymphodepletion chemotherapy. The disease remained refractory, which led the team to recommend dual CD19/CD20 CAR-T cell therapy.
Rodney's family reached out for help finding an advanced option. CancerFax organised his records for review and helped identify dual-target CAR-T at Lu Daopei Hospital as a possible path, then coordinated the next steps.
After arrival and evaluation, Rodney's own (autologous) T cells were collected and manufactured into dual CD19/CD20 CAR-T cells in preparation for infusion.
Rodney received the infusion of autologous dual CD19/CD20 CAR-T cells. The post-infusion course was smooth, with no cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity (ICANS), and he remained clinically stable.
Peripheral blood monitoring tracked clear CAR-T cell expansion. Levels were modest at Day 4, rose by Day 7, and by Day 10 the CAR19+ population reached around 43% and the CAR20+ population around 33% of CD3+ T cells, with a balanced spread across CD4+ and CD8+ subsets.
This strong, well-tolerated early expansion is an encouraging engraftment signal. It is not yet a measure of tumour response. Formal response assessment is planned for the weeks ahead.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Rodney Is Today
At the most recent follow-up, Day 10 after infusion, Rodney was clinically stable and doing well. He continues on a tailored oral regimen with regular monitoring of his blood counts, liver and kidney function, and inflammatory markers, in line with his discharge plan.
It is still early. The treatment response will be assessed over the coming weeks through formal restaging, and Rodney remains under ongoing monitoring. CancerFax will continue to follow his progress alongside the treating team. This page reflects where his journey stands today and will be updated as more is confirmed.
β"These first days have gone better than we dared hope. We are taking it one step at a time."ββ Rodney's family
What Other Families Can Learn
A few practical takeaways for families facing relapsed or refractory aggressive lymphoma.
When standard regimens no longer control the disease, specialist review can surface advanced approaches such as cell therapy that may not be visible at home.
High-risk features like double-expressor status and a BCL2 rearrangement shape which treatments make sense, so a complete pathology and genetic workup matters.
A treatment that is delivered without severe toxicity allows an older patient to stay stable through the critical early period.
Records, translation, hospital communication, and travel can be managed with the right support, which removes much of the burden from the family.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.